RVPH revivapharma.com Final Profit

Official company branding of Reviva Pharmaceuticals Holdings Inc. (RVPH)

The net financial flow of Reviva Pharmaceuticals (RVPH) in GURU.Markets exhibits volatile dynamics, where the -0.02 level serves as a critical mark. Stable demand for psychiatric care provides the business with defensive qualities, yet the growth of Reviva Pharmaceuticals (RVPH) relies on the expansion of brilarazine for schizophrenia. The company currently operates within a clinical ecosystem where commercial success and survival depend entirely on FDA approval.

Net Income: Reviva Pharmaceuticals, Inc. (RVPH) for 07/04/2022 - 05/16/2026

Comprehensive metric breakdowns and analytics for Reviva Pharmaceuticals Holdings, Inc. (RVPH)

- stock value and consensus price forecast:
Market Price Reviva Pharmaceuticals, Inc.|RVPH - Price Target Chart
- market capitalization data:
Market Value Reviva Pharmaceuticals, Inc.|RVPH - Enterprise Value
- business book valuation details:
Net Asset Value per Share Reviva Pharmaceuticals|RVPH - Company Net Assets|Market Value to Book Value Ratio revivapharma.com|RVPH - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Reviva Pharmaceuticals|RVPH - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Reviva Pharmaceuticals Holdings Inc.|RVPH - Company Aggregate Debts|Debts to Book Capitalization Reviva Pharmaceuticals, Inc.|RVPH - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Reviva Pharmaceuticals|Critical Liquidity Ratio revivapharma.com
- company profitability and valuation multiples indicators:
RVPH - Net Profit
Fundamental valuation:Reviva Pharmaceuticals
Mass-produced product of Reviva Pharmaceuticals Holdings Inc.

This indicator captures the net financial result after deducting all operating and tax expenses, allowing for an assessment of the business's real value and the control premium. By analyzing the bottom-line profit of Reviva Pharmaceuticals (RVPH), a conservative investor weighs current losses against the commercialization potential of brilaroxazine and M&A prospects, which determines the long-term consensus value of the assets of Reviva Pharmaceuticals (RVPH).

Key competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|RGC: Final Profit|Net Profit AXSM|ACAD - Company Net Income|Xenon Pharmaceuticals Inc - Net Income|Viking Therapeutics Corp - Company Net Income|Supernus Pharmaceuticals - Net Profit|Net Financial Result catalystpharma.com CPRX|DNLI (Denali Therapeutics Inc.) - Net Income|HRMY (Harmony Biosciences Inc) - Company Net Income|BHVN (Biohaven Pharmaceutical) - Net Profit|Net Profit Amylyx Corp|Net Income TRVI (Trevi Therapeutics)|PRAX (praxismedicines.com) - Final Profit|Company Net Income Anavex Life Sciences Corp. AVXL|CBLL (CeriBell Inc) - Profit After Tax|Prothena Biosciences - Net Profit|Final Profit ALEC (Alector, Inc.)|ANNX: Net Profit|Omeros (OMER) - Net Profit|Company Net Income Neurogene|ACIU: Final Profit|Company Net Income Voyager Pharma (VYGR)|Net Income Neumora Corp NMRA|Net Profit SCLX (Scilex Holding Company)|Net Profit tevogen.com TVGN|Alpha Cognition Corp - Net Profit|cogrx.com (CGTX) - Net Income|IKT: Net Profit|Company Net Income Cassava Pharma (SAVA)|Net Income ASRT|Net Profit Coya|Net Income VTGN (Vistagen Therapeutics)|Profit After Payment of Taxes OVID|Net Profit ABOS (Acumen Pharma)|Net Financial Result CervoMed Corporation (CRVO)|Alterity Therapeutics Ltd - Net Profit|Clene Inc. (CLNN) - Net Income|PEPG: Net Profit|jupiterneurosciences.com (JUNS) - Net Profit|Company Net Income Relmada|Company Net Income ANVS|Company Net Income Grace Therapeutics, Inc. (GRCE)|Net Financial Result fireflyneuro.com|Company Net Income Klotho Neurosciences KLTO|Final Profit NRSN|MTVA: Net Income|NRXS: Company Net Income|heliusmedical.com (HSDT) - Company Net Income|Profit After Tax PASG (Passage Bio)|NEUP (Neuphoria Therapeutics, Inc.) - Net Profit|NERV: Final Profit|Company Net Income Athira (ATHA)|Addex - Company Profit|Net Profit ALZN (Alzamend Neuro)|Cyclerion Therapeutics Inc. (CYCN) - Company Net Income|PTIX: Net Income|KTTA - Net Profit|cortigent.com (CRGT) - Company Net Income|Avenue Therapeutics Inc - Final Profit|Company Net Income Brainstorm Cell|Company Net Income caratherapeutics.com CARA|Company Net Income Chromocell Therapeutics Corp. (CHRO)|ELYM (eliemtx.com) - Final Profit|Net Profit ITCI (Intra-Cellular Therapies, Inc.)|Longboard (LBPH) - Company Net Income|MRNS: Net Income|NKGN: Company Net Income|NRBO: Net Profit|SAGE - Net Financial Result|Net Income SNPX|Company Net Income TRVN|Net Profit VIGL|Net Profit Anew Medical Inc. (WENA)|Cerevel Therapeutics, Inc. - Net Income